Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer

NCT02857270 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02857270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02857270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
September 29, 2016
Completion date
October 24, 2022
Enrollment
210 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, colorectal cancer, metastatic melanoma, metastatic non-small cell lung cancer